Revvity Q4 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Strong Earnings Performance: Revvity reported a Q4 non-GAAP EPS of $1.70, beating expectations by $0.12, which highlights the company's robust profitability and boosts investor confidence.
- Solid Revenue Growth: The company achieved Q4 revenue of $772 million, representing a 5.9% year-over-year increase and exceeding market expectations by $8.93 million, indicating strong competitive positioning and sustained customer demand.
- Optimistic 2026 Outlook: Revvity forecasts total revenue for 2026 to be between $2.96 billion and $2.99 billion, surpassing the consensus of $2.94 billion, with organic revenue growth projected at 2-3%, showcasing future growth potential.
- Adjusted Earnings Guidance: The company anticipates adjusted EPS for 2026 to range from $5.35 to $5.45, slightly above the consensus of $5.32, further reflecting confidence in its future profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVTY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVTY
Wall Street analysts forecast RVTY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVTY is 113.38 USD with a low forecast of 105.00 USD and a high forecast of 123.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 108.490
Low
105.00
Averages
113.38
High
123.00
Current: 108.490
Low
105.00
Averages
113.38
High
123.00
About RVTY
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Revvity Reports Fourth Quarter Earnings Growth
- Earnings Growth: Revvity, Inc. reported a fourth-quarter net income of $98.36 million, translating to an earnings per share (EPS) of $0.87, which marks a significant increase from last year's $94.65 million and $0.78 EPS, indicating enhanced profitability.
- Adjusted Earnings: Excluding certain items, Revvity's adjusted EPS stood at $1.70, showcasing strong performance in its core operations and further solidifying its market position.
- Revenue Increase: The company's revenue rose by 5.9% year-over-year to $772.06 million, compared to $729.37 million last year, reflecting the effectiveness of its sales strategies and increased market demand.
- Financial Health: The overall improvement in financial performance not only boosts investor confidence but also provides a stronger capital base for future expansion and investments, signaling sustained competitiveness in the industry.
Continue Reading
Revvity Reports 6% Revenue Growth in Q4
- Financial Performance Overview: Revvity reported Q4 2025 revenue of $772 million, reflecting a 6% increase from $729 million in the same period last year, indicating the company's stable growth potential in the market, although GAAP EPS slightly rose to $0.87 from $0.78 year-over-year.
- Adjusted Earnings Performance: The adjusted EPS for Q4 was $1.70, a 19.8% increase from $1.42 a year ago, demonstrating enhanced profitability in ongoing operations, despite a decline in GAAP operating profit margin from 16.3% to 14.5%, reflecting cost pressures.
- 2026 Outlook: The company forecasts total revenue for 2026 to be between $2.96 billion and $2.99 billion, with expected organic growth of 2%-3%, showcasing management's confidence in future market conditions and aiming to drive long-term growth through continued investment and innovation.
- Segment Performance: In the Life Sciences segment, Q4 revenue was $382 million, up 2%, while the Diagnostics segment saw a 10% revenue increase to $390 million, highlighting Revvity's adaptability and growth potential across different markets, particularly in the rapidly evolving diagnostics sector.
Continue Reading